Delivery Order SPE2DB22D3011-SPE2DB25FQ2EB
- Not listed
- The Defense Logistics Agency awarded a $4,343.52 firm fixed price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 29, 2025, with completion targeted for July 30, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $3,280.54 and is scheduled for completion by August 1, 2025. The contract represents a child award under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) valued at $9,027.48 under a firm fixed-price contract type. The award was issued on July 28, 2025, with an ultimate completion date of July 29, 2025, and was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs,...
- The Defense Logistics Agency awarded a $3,198.50 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for XELJANZ XR 11 MG tablets in 30-count units. This is a firm fixed price, non-set-aside contract with performance completion scheduled for July 29, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is fulfilling this order from its corporate office location in the same city. The contract represents a child delivery order under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of XELJANZ XR 11 mg tablets in quantities of 30 units. This firm fixed price delivery order, valued at $8,141.67, represents a non-competitive set-aside procurement and is scheduled for ultimate completion by August 1, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency for XELJANZ XR 11 mg tablets in 30-count unit doses, valued at $18,565.52 under a firm fixed price contract type. The award, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, carries no set-aside designation, indicating competitive award to this qualified pharmaceutical distributor. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $15,418.01 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This competitively awarded, firm fixed price delivery order is set to be completed by July 25, 2025, and represents a non-set-aside procurement. The award was issued on July 24, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $20,369.56 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count packaging) on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-set-aside, competitively awarded contract employs firm fixed-price terms and represents a child delivery order under AmerisourceBergen's larger contract vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $3,796.45 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's corporate...
- The Defense Logistics Agency awarded a $16,119.77 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 30, 2025, with completion scheduled for July 31, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ2EBDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $17,873.07 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on August 8, 2025, for XELJANZ XR 11 mg tablets (30-count packages). The award, which carries an ultimate completion date of August 11, 2025, represents a non-set-aside competitive procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026 that enables the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. The Defense Logistics Agency's Medical Supply Chain utilizes these delivery orders to fulfill critical pharmaceutical needs across the Department of Defense and other federal healthcare systems. XELJANZ XR is a disease-modifying antirheumatic drug commonly used in military and veteran healthcare settings for treating rheumatoid arthritis and related conditions. AmerisourceBergen's role as a Pharmaceutical Prime Vendor under the DLA framework demonstrates its capability to meet federal procurement requirements through competitive processes and deliver specialized medications efficiently to support military readiness and healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.9k | 8/8/25 |